• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Introduction to 2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid (CAS No. 1483293-27-1)

2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1483293-27-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This spirocyclic carboxylic acid derivative exhibits a unique structural framework, characterized by a spiro linkage between two cycloalkane rings, which contributes to its distinct chemical and biological properties. The presence of a p-tolyl (para-methylphenyl) group at the second carbon position enhances its molecular complexity and potential utility in various synthetic applications.

The compound’s structure, featuring a heptane core with a spiro connection, makes it an intriguing candidate for further exploration in drug design and development. Spirocyclic compounds are known for their structural rigidity and tunable electronic properties, which can be leveraged to modulate biological activity. In particular, the spiro[3.3]heptane scaffold has been investigated for its potential in creating novel pharmacophores that interact with biological targets in unique ways.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding affinities and interactions of such compounds with biological receptors. Studies suggest that the p-tolyl substituent may enhance solubility and metabolic stability, making 2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid a promising intermediate in the synthesis of bioactive molecules. The carboxylic acid moiety at the terminal position further extends its utility as a versatile building block for more complex derivatives.

In the realm of medicinal chemistry, the synthesis of spirocyclic carboxylic acids has been a focus due to their potential as scaffolds for therapeutic agents. The unique conformational constraints imposed by the spiro linkage can lead to high selectivity in binding interactions, which is crucial for developing drugs with minimal side effects. For instance, derivatives of this compound have been explored as potential inhibitors of enzymes involved in inflammatory pathways, showcasing their therapeutic relevance.

The chemical synthesis of 2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid involves multi-step organic transformations, including cyclization reactions and functional group modifications. The spirocyclic core is typically formed through intramolecular reactions that require precise control over reaction conditions to ensure high yield and purity. Advances in catalytic methods have improved the efficiency of these synthetic routes, making it feasible to produce larger quantities of the compound for research purposes.

From a biochemical perspective, the compound’s ability to interact with proteins and other biomolecules has been studied using various spectroscopic techniques. NMR spectroscopy has been particularly useful in elucidating its three-dimensional structure, while X-ray crystallography has provided insights into its molecular packing and interactions within crystal lattices. These structural details are essential for understanding its biological activity and optimizing its pharmacological properties.

One notable area of research involving 2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid is its potential application in designing small-molecule probes for biochemical assays. Its rigid structure and well-defined functional groups make it an excellent candidate for creating tools that can interact specifically with target proteins or enzymes. Such probes are invaluable in drug discovery pipelines, as they help researchers identify new therapeutic targets and evaluate the efficacy of potential drug candidates.

The compound’s stability under various storage conditions has also been evaluated, ensuring its suitability for long-term research applications. Studies have demonstrated that when stored under inert atmospheres at controlled temperatures, 2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid maintains its integrity over extended periods. This stability is critical for maintaining consistency in experimental results across different research groups.

In conclusion, 2-(p-Tolyl)spiro[3.3]heptane-2-carboxylic acid (CAS No. 1483293-27-1) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and potential biological applications. Its spirocyclic framework, combined with the p-tolyl substituent, offers a versatile platform for designing novel bioactive molecules. As research continues to uncover new therapeutic possibilities, this compound is poised to play a crucial role in the development of next-generation drugs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)